PATENT CLAIM ANALYSIS

Application Number: 15985300
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "457000"]

Abstract:
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Claim (Index 38):
An oral pharmaceutical composition for once-daily administration from 0 to 4 hours before bedtime to a human patient with Parkinson's disease receiving levodopa-based therapy, comprising:\n (a) an amount effective to reduce, relative to placebo, dyskinesia in said human patient with Parkinson's disease receiving levodopa-based therapy, of a drug chosen from amantadine and pharmaceutically acceptable salts thereof; and (b) at least one means for releasing said drug to provide (i) a Cmax of from about 1.0 to about 2.8 ng/mL per mg of amantadine, and (ii) an AUC 0-inf  of from about 40 to about 75 ng*hr/mL per mg of amantadine upon administration of a single dose of the composition to a healthy human subject in a fasted state; wherein said dyskinesia is measured by the Unified Dyskinesia Rating Scale (UDysRS).

Metadata:
- Claim Count in Document: 101.0
- Percentile: 93.0
- Lexical Diversity: 1.30769
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15428899', '15428878', '12959321', '15430084', '14307195']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7581670953352735
- 35 USC 102 Novelty (BERT): 0.5906718377692627
- Combined Prediction Score: 0.7414175695786724
- Mean Citation Score: 543.4879099999998
- Max Citation Score: 559.00256
- Similarity Product: 406.1672902659988

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test